Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL7042765 | 1.00 | LMNA (0.41) | LMNAALDH1A1THRBTSHRTDP1 | |
| SCHEMBL223178 | 0.92 | — | — | |
| SCHEMBL924825 | 0.92 | — | — | |
| SCHEMBL12650465 | 0.92 | — | — | |
| Propylene Glycol SCHEMBL28789008 | 0.84 | TDP1 (0.53) | LMNAALDH1A1THRBTSHRTDP1 | |
| SCHEMBL16422 | 0.82 | LMNA (0.39) | LMNATHRBTSHRTDP1 | |
| SCHEMBL3904266 | 0.82 | LMNA (0.39) | LMNATHRBTSHRTDP1 | |
| SCHEMBL11141509 | 0.82 | LMNA (0.39) | LMNATHRBTSHRTDP1 | |
| SCHEMBL11138291 | 0.82 | LMNA (0.39) | LMNATHRBTSHRTDP1 | |
| SCHEMBL9450423 | 0.82 | LMNA (0.39) | LMNATHRBTSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3560499-B1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-1778240-B1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3560499-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-2275107-B1 | Combinations for the treatment of diseases involving cell proliferation | BOEHRINGER INGELHEIM INT (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-8591895-B2 | Combinations for the treatment of diseases involving cell proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-26 | — | — | US | disclosed |
| US-20120107312-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-8143247-B2 | Combinations for the treatment of diseases involving cell proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| EP-2409706-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | Boehringer Ingelheim International GmbH (DE) | 2012-01-25 | — | — | EP | disclosed |
| US-8058270-B2 | Dihydropteridinones for the treatment of cancer diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-15 | — | — | US | disclosed |
| EP-1778238-B1 | DIHYDROPTERIDINONE INFUSION SOLUTION HAVING A LONG SHELF LIFE | BOEHRINGER INGELHEIM INT (DE) | 2011-10-12 | — | — | EP | disclosed |
| US-6861422-B2 | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-01 | — | — | US | disclosed |
| US-20050014761-A1 | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | 2005-01-20 | — | — | US | disclosed |
| US-20050014760-A1 | Methods of treating diseases or conditions using dihydropteridinone compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-01-20 | — | — | US | disclosed |
| US-6806272-B2 | ANTIINFLAMMATORY AND ANTIPROLIFERATIVE ACTIVITY | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-10-19 | — | — | US | disclosed |
| WO-2004076454-A1 | DIHYDROPTERIDINONES, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-09-10 | — | — | WO | disclosed |
| US-20040176380-A1 | New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
| US-20040147524-A1 | Methods of using dihydropteridinones | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-29 | — | — | US | disclosed |
| EP-1427730-A1 | NOVEL DIHYDROPTERIDINONES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-06-16 | — | — | EP | disclosed |
| US-20040029885-A1 | New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-02-12 | — | — | US | disclosed |
| WO-2003020722-A1 | NOVEL DIHYDROPTERIDINONES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176380-A1 | New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | QDPR, DHPS, DRD5 | LMNA 2312/4885ALDH1A1 608/4885THRB 3057/4885 |
| US-20040029885-A1 | New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | QDPR, DHPS, DRD4 | LMNA 3291/4885ALDH1A1 889/4885THRB 3016/4885 |
| US-20050014760-A1 | Methods of treating diseases or conditions using dihydropteridinone compounds | QDPR, DHPS, DHFR | LMNA 1228/4885ALDH1A1 742/4885THRB 1202/4885 |
| US-20120107312-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | CCNA1, MKI67, CCNA2 | LMNA 1168/4885ALDH1A1 1053/4885THRB 1043/4885 |
| US-20040147524-A1 | Methods of using dihydropteridinones | QDPR, DHPS, DPYD | LMNA 2998/4885ALDH1A1 820/4885THRB 2340/4885 |
| US-20050014761-A1 | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions | QDPR, DHPS, DHODH | LMNA 1883/4885ALDH1A1 759/4885THRB 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.